Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingWe are a leading provider of ophthalmic disease management solutions in North America, and were founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For over a decade, we have partnered with U.S. eyecare professionals to develop a comprehensive portfolio of high-quality products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Business segments
Jun 2026 · $70.7MThe company’s own SEC segment disclosure.
- Product Sales Net$70.6M100%
- Other$90.0K0%
Harrow, Inc. (HROW) reported revenue of $44M in Q1 2026 (quarter ended Mar 31, 2026), down 7.6% from the same quarter a year earlier. That came with a gross margin of 61% and net loss of $28M. For the full year FY2025, revenue was $272M (+36% year on year) and net income −$5.1M. Its largest product in Jun 2026 was Product Sales Net at $71M, 100% of the disclosed total, well ahead of Other at 0.1%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #26 of 29 by Smart Score